Skip to main content

Advertisement

SpringerLink
Log in

Tumoren und Transplantation

Inzidenz und Management

Tumors and transplantation

Incidence and management

  • Leitthema
  • Published:
Der Nephrologe Aims and scope

Zusammenfassung

Das Risiko für eine Tumorentwicklung nach Transplantation ist im Vergleich zur Normalbevölkerung erhöht, und die Prognose von Patienten mit Tumor nach Transplantation ist meist eingeschränkt. Deswegen sollte die Entwicklung eines Tumors nach Transplantation verhindert werden. Daraus ergeben sich wichtige Implikationen für das Management bei Transplantation hinsichtlich einer möglichen Tumorentwicklung. Tumoren nach Transplantation können aus einer vorherigen Tumorerkrankung rekurrieren, durch den Spender übertragen werden oder neu entstehen. Letztlich ist bei Durchführung der Transplantation immer das Risiko einer Tumorentwicklung mit dem Nutzen der Transplantation abzuwägen und sollte individuell für die einzelne Spender-Empfänger-Konstellation erfolgen. Der Patient sollte über das Risiko einer Tumorentwicklung (Rekurrenz, Transmission oder Neuentstehung) bei der Listung zur Transplantation aufgeklärt werden. Dieser Übersichtsartikel fasst die Daten zur jeweiligen Inzidenz der Tumorentwicklung nach Transplantation zusammen und liefert somit Anhaltspunkte für die Aufklärung und das Management von Patienten hinsichtlich der Tumorentwicklung nach Transplantation.

Abstract

The risk of developing tumors after transplantation is increased compared to the normal population and the prognosis of patients with a malignant disease after transplantation is often limited; therefore, avoidance of malignancies after transplantation is essential. This leads to important implications for the management of transplantation related to the development of post-transplant malignancies. Malignancies can reoccur from a previously diagnosed and treated malignancy, be transmitted by the donor or develop de novo post-transplantation. Ultimately, in the setting of transplantation the risk for development of a malignant disease needs to be balanced against the benefits of transplantation and should be assessed on an individual basis for the specific donor-recipient constellation. The patient needs to be informed about the potential risks for the development of malignancies (e.g. recurrence, transmission or de novo) when being placed on the list for transplantation. This review summarizes the data for the incidence of malignant diseases after transplantation and provides the basis for informed consent and the management of patients with regard to the development of malignant diseases after transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Anonymous (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–155

    Google Scholar 

  2. Birkeland SA, Storm HH (2002) Risk for tumor and other disease transmission by transplantation: a population-based study of unrecognized malignancies and other diseases in organ donors. Transplantation 74:1409–1413

    Article  PubMed  Google Scholar 

  3. Buell JF, Gross T, Alloway RR et al (2005) Central nervous system tumors in donors: misdiagnosis carries a high morbidity and mortality. Transplant Proc 37:583–584

    Article  PubMed  CAS  Google Scholar 

  4. Buell JF, Trofe J, Sethuraman G et al (2003) Donors with central nervous system malignancies: are they truly safe? Transplantation 76:340–343

    Article  PubMed  Google Scholar 

  5. Caillard S, Lamy FX, Quelen C et al (2012) Epidemiology of Posttransplant Lymphoproliferative disorders in adult kidney and kidney pancreas recipients: report of the french registry and analysis of subgroups of lymphomas. Am J Transplant 12:682–693

    Article  PubMed  CAS  Google Scholar 

  6. Desai R, Collett D, Watson CJ et al (2014) Estimated risk of cancer transmission from organ donor to graft recipient in a national transplantation registry. Br J Surg 101:768–774

    Article  PubMed  CAS  Google Scholar 

  7. Dholakia S, Johns R, Muirhead L et al (2015) Renal donors with prostate cancer, no longer a reason to decline. Transplant Rev (Orlando). doi:10.1016/j.trre.2015.06.001

    Google Scholar 

  8. Engels EA, Castenson D, Pfeiffer RM et al (2014) Cancers among US organ donors: a comparison of transplant and cancer registry diagnoses. Am J Transplant 14:1376–1382

    Article  PubMed  CAS  Google Scholar 

  9. Euvrard S, Morelon E, Rostaing L et al (2012) Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367:329–339

    Article  PubMed  CAS  Google Scholar 

  10. Jimenez-Zepeda VH, Heilman RL, Engel RA et al (2011) Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants. Transplantation 92:570–574

    Article  PubMed  Google Scholar 

  11. Kaiser C, Laux G, Eick D et al (1999) The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol 73:4481–4484

    PubMed  CAS  PubMed Central  Google Scholar 

  12. Kasiske BL, Cangro CB, Hariharan S et al (2001) The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant 1(Suppl 2):3–95

    PubMed  Google Scholar 

  13. Kasiske BL, Snyder JJ, Gilbertson DT et al (2004) Cancer after kidney transplantation in the United States. Am J Transplant 4:905–913

    Article  PubMed  Google Scholar 

  14. Kauffman HM, Cherikh WS, Mcbride MA et al (2007) Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update. Transplantation 84:272–274

    Article  PubMed  Google Scholar 

  15. Knoll G, Cockfield S, Blydt-Hansen T et al (2005) Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 173:1181–1184

    Article  PubMed  PubMed Central  Google Scholar 

  16. Knoll G, Cockfield S, Blydt-Hansen T et al (2005) Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ 173:S1–25

    Article  PubMed  PubMed Central  Google Scholar 

  17. Kuhlmann U, Böhler J, Luft FC, Alsche MD, Kunzendorf U (2015) Nephrologie. Pathophysiologie – Klinik – Nierenersatzverfahren, 6. Auflage, Thieme, Stuttgart

  18. Morath C, Schwenger V, Schmidt J et al (2005) Transmission of malignancy with solid organ transplants. Transplantation 80:S164–166

    Article  PubMed  Google Scholar 

  19. Myron KH, Mcbride MA, Cherikh WS et al (2002) Transplant tumor registry: donor related malignancies. Transplantation 74:358–362

    Article  Google Scholar 

  20. Penn I (1993) The effect of immunosuppression on pre-existing cancers. Transplantation 55:742–747

    Article  PubMed  CAS  Google Scholar 

  21. Penn I (1995) Primary kidney tumors before and after renal transplantation. Transplantation 59:480–485

    Article  PubMed  CAS  Google Scholar 

  22. Schwarz A, Vatandaslar S, Merkel S et al (2007) Renal cell carcinoma in transplant recipients with acquired cystic kidney disease. Clin J Am Soc Nephrol 2:750–756

    Article  PubMed  Google Scholar 

  23. Stallone G, Infante B, Grandaliano G (2015) Management and prevention of post-transplant malignancies in kidney transplant recipients. Clin Kidney J 8:637–644

    Article  PubMed  PubMed Central  Google Scholar 

  24. Stallone G, Schena A, Infante B et al (2005) Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352:1317–1323

    Article  PubMed  CAS  Google Scholar 

  25. Trappe R, Oertel S, Leblond V et al (2012) Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13:196–206

    Article  PubMed  CAS  Google Scholar 

  26. Ulrich C, Arnold R, Frei U et al (2014) Skin changes following organ transplantation: an interdisciplinary challenge. Dtsch Arztebl Int 111:188–194

    PubMed  PubMed Central  Google Scholar 

  27. Warrens AN, Birch R, Collett D et al (2012) Advising potential recipients on the use of organs from donors with primary central nervous system tumors. Transplantation 93:348–353

    Article  PubMed  Google Scholar 

  28. Watson CJ, Roberts R, Wright KA et al (2010) How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant 10:1437–1444

    Article  PubMed  CAS  Google Scholar 

  29. Wimmer CD, Rentsch M, Crispin A et al (2007) The janus face of immunosuppression – de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 71:1271–1278

    Article  PubMed  CAS  Google Scholar 

  30. Xiao D, Craig JC, Chapman JR et al (2013) Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant 13:2645–2652

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin IV, Nieren- und Hochdruckkrankheiten, Universitätsklinikum Schleswig-Holstein, Christian-Albrechts-Universität Kiel, Schittenhelmstr. 12, 24105, Kiel, Deutschland

    T. Feldkamp & U. Kunzendorf

Authors
  1. T. Feldkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Kunzendorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Feldkamp.

Ethics declarations

Interessenkonflikt

T. Feldkamp weist auf folgende Beziehung hin: T. Feldkamp ist als Referent tätig für die Firmen Alexion, Amgen, Astellas, Bristol-Myers-Squibb, Novartis, und Roche und erhält Forschungsstipendien von den Firmen Astute Medical France und Roche. U. Kunzendorf gibt an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Additional information

Redaktion

M. Zeier, Heidelberg

J. Hoyer, Marburg

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feldkamp, T., Kunzendorf, U. Tumoren und Transplantation. Nephrologe 11, 41–49 (2016). https://doi.org/10.1007/s11560-015-0023-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-015-0023-4

Schlüsselwörter

Keywords

Search

Navigation